▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Novo Nordisk (NYSE: NVO)

$51.83

(2.9%)

$1.45

Price as of August 15, 2025, 3:58 p.m. ET

Novo Nordisk Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
NVO	-61.12%	+71.64%	+11.40%	+45,494%
S&P	+16.35%	+91.23%	+13.83%	+4,888%

Novo Nordisk Company Info

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

News & Analysis

The Fool has written over 500 articles on Novo Nordisk.

Featured Article

1 Stock Down 40% This Year to Buy and Hold

This might be a wonderful entry point for long-term investors.

Prosper Junior Bakiny | Aug 17, 2025

Featured Article

Why Novo Nordisk Flew Almost 3% Higher on Friday

It seems to be holding off on price adjustments demanded by President Trump.

Eric Volkman | Aug 15, 2025

Best Stock to Buy: Novo Nordisk Stock vs. UnitedHealth Stock

Parkev Tatevosian, CFA | Aug 14, 2025

Healthcare stocks are underperforming this year due to unfavorable government policy.

Why Novo Nordisk Stock Topped the Market Today

Eric Volkman | Aug 13, 2025

Bullishness slowly seems to be coming back to the beleaguered drugmaker.

Novo Nordisk Stock: Buy or Sell?

Parkev Tatevosian, CFA | Aug 12, 2025

News from a competitor is increasing enthusiasm for Novo Nordisk stock.

4 of the Most Undervalued Stocks in the Market Right Now

Mark Roussin, CPA | Aug 11, 2025

They all offer great value right now.

2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade

Cory Renauer | Aug 10, 2025

These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth.

Why Novo Nordisk Stock Flew Higher on Friday

Eric Volkman | Aug 8, 2025

It looked good next to a company that has been stealing its thunder lately.

Valuation

Podcast Episodes

Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease

Explaining diabetes, its various treatment options, and what the future may have in store for this disease.

Todd Campbell and Gaby Lapera | Jun 18, 2016

Earnings Transcripts

Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript

NVO earnings call for the period ending December 31, 2024.

Motley Fool Transcribing | Feb 5, 2025

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript

NVO earnings call for the period ending September 30, 2024.

Motley Fool Transcribing | Nov 6, 2024

Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript

NVO earnings call for the period ending June 30, 2024.

Motley Fool Transcribing | Aug 7, 2024

Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript

NVO earnings call for the period ending March 31, 2024.

Motley Fool Transcribing | May 2, 2024

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services